Explore the words cloud of the DIVE into AD project. It provides you a very rough idea of what is the project "DIVE into AD" about.
The following table provides information about the project.
Coordinator |
UNIVERSITE DE GENEVE
Organization address contact info |
Coordinator Country | Switzerland [CH] |
Total cost | 278˙840 € |
EC max contribution | 278˙840 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2018 |
Funding Scheme | MSCA-IF-GF |
Starting year | 2020 |
Duration (year-month-day) | from 2020-08-01 to 2023-07-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | UNIVERSITE DE GENEVE | CH (GENEVE) | coordinator | 278˙840.00 |
2 | THE GENERAL HOSPITAL CORPORATION | US (BOSTON MA) | partner | 0.00 |
Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reach 19 millions by 2050. Alzheimer’s disease (AD) is responsible for the vast majority of dementia cases. However there is still not a single available treatment that modifies the course of disease. Therefore, the development of innovative approaches to better understand the pathophysiology and ultimately treat patients must be a priority. This project aims to understand the determinants of the diversity of AD clinical phenotypes through the deep analysis of pathological variants of the tau protein. As the accumulation of Aβ peptide has long been considered a causative event in AD, most therapeutic approaches have targeted Aβ metabolism, but unsuccessfully. Modern biomarkers, have confirmed that the brain deposition of tau pathology, the other hallmark of AD, correlates much better with human cognition and neurodegeneration. Recently, it was shown that tau behaves like a prion and can spread from one neuron to another. Moreover, tau strains or conformers seem to template native tau and propagate the pathological conformation with high fidelity. Discrete tau strains generate distinct aggregates morphology or patterns of neuronal vulnerability. I postulate that different strains of tau are responsible for the variability of AD and may determine the progression rate, gender differences or clinical expression. Therefore, my objective is to develop the technologies to identify tau strains signatures in distinct AD phenotypes. In particular, I plan to develop and optimize biosensor cell lines that sensitively detect tau strains from human brain samples and cerebrospinal fluid, and characterize respective repertoire of tau strains. Understanding AD heterogeneity would potentially increase our ability to take care of every individual patient. In addition, this work could lead to the development of biomarkers and novel targeted therapies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIVE INTO AD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DIVE INTO AD" are provided by the European Opendata Portal: CORDIS opendata.